已收录 268921 条政策
 政策提纲
  • 暂无提纲
Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature
[摘要] BackgroundMultiple ground-glass nodules (mGGNs) in the lung has been defined as synchronous multiple primary lung cancer (SMPLC), it is has been very difficult challenging to differentiate SMPLC from intrapulmonary metastases, and its treatment remains controversial.Case presentationWe report a case simultaneously involving mGGNs and lung adenocarcinoma harboring primary EGFR-T790M mutation, in which the patient underwent the radical resection of lesions in the left upper lung, and continued the osimertinib treatment for the residual mGGNs in all lobes of the right lung. These mGGNs displayed different responses to osimertinib.ConclusionsWe reported a successful strategy on the postoperative treatment for mGGNs. For those that cannot be completely resected, the chemotherapy, radiotherapy, stereotactic body radiation therapy, immunotherapy and targeted therapy have been performed instead. The EGFR-TKI therapy strategy showed significant advantages, but how to achieve even better therapeutic effect needs more researches.
[发布日期] 2022-12-09 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Multiple ground-glass nodules (mGGNs);Synchronous multiple primary lung cancer (SMPLC);Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文